Introduction
Pathology laboratories play a crucial role in the diagnosis and treatment of various diseases. However, these labs are often plagued by labor shortages, rising caseloads, and an antiquated process of preparing tissue samples. Clarapath Inc. is a company that aims to modernize and transform how pathology laboratories process tissue. In this article, we will explore how Clarapath is using robotics and automation to revolutionize the pathology industry.
Listen to this article
|
Listen to this article |
SectionStar is a tissue sectioning and transfer robot designed to increase capacity, reliability, and consistency. | Source: Clarapath
While robotics and automated systems have been introduced in healthcare settings as a way to alleviate workforce issues and standardize practices, most of the progress has been aimed at surgical robots or physical rehabilitation. Clarapath Inc. hopes to change this.
Last week, the Hawthorne, N.Y.-based company announced that it has raised $36 million in Series B-1 funding. Clarapath said it aims to modernize and transform how pathology laboratories process tissue. This latest round brings its total funding to $75 million.
The company said its SectionStar system combines robotics, artificial intelligence, and automation to modernize how labs process tissue samples. With the latest round of funding, Clarapath asserted that it will develop and deploy “a new category of healthcare robotics, machine vision, and digital automation tools, elevating the standard of care for hospitals and patients.”
Pathology can benefit from automation
The discipline of pathology involves the microscopic examination of cells and tissue, Clarapath explained. This work underpins the research, diagnosis, and treatment pathways of nearly every disease type, including cancer, autoimmune conditions, degenerative diseases, and more.
More than 12 million human and veterinary biopsies are performed each year in the U.S., with millions more performed for biopharmaceutical drug safety. Laboratories face a multi-pronged crisis, including severe labor shortages; rising caseloads; and an antiquated, manual process of preparing tissue samples, according to Clarapath.
“For too long, pathology laboratories have not seen the level of technology innovation that other areas of medicine have seen,” said Gregg Sossaman, M.D., chair of pathology and laboratory medicine at investor Ochsner Health and incoming president of the American Society for Clinical Pathology. “Clarapath demonstrates the right mix of technical, robotic expertise coupled with healthcare workflow experience.”
Clarapath says SectionStar can improve slide quality, decrease turnaround time, and reduce cost. | Source: Clarapath
Clarapath to commercialize SectionStar
Northwell Ventures led Clarapath’s Section B-1 round, which also included new strategic investors including CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Ventures.
“Innovation is embedded in Northwell’s culture and integral to the way we approach investment in novel solutions which improve patient care and lower cost.” said Rich Mulry, CEO of Northwell Holdings. “We identified Clarapath seven years ago as a company with a bold vision to radically change laboratory medicine and are committed to continued support of their progressive journey which will transform medical diagnostics.”
With the new capital, Clarapath said it plans to further accelerate the commercialization of SectionStar. It will also use the funds to expand its sales, services, and precision manufacturing capabilities, as well as to continue research and development.
“Our strategic investors share in our mission to significantly overhaul this critical aspect of patient care that has long been overlooked,” stated Eric Feinstein, CEO of Clarapath.
“As labs adopt digital pathology downstream, automation in prior steps is crucial to establish consistent results and provide best-in-class samples for diagnostic review,” he added. “Our automation and new digital tools capture and aggregate never-before-seen data, ultimately benefiting patients with faster results and less subjectivity.”
Conclusion
Clarapath Inc. is revolutionizing the pathology industry by introducing robotics and automation to modernize and transform how pathology laboratories process tissue. With its flagship robot SectionStar, Clarapath aims to increase capacity, reliability, and consistency in tissue sectioning and transfer. The company has raised $36 million in Series B-1 funding and plans to use the funds to accelerate the commercialization of SectionStar and expand its sales, services, and precision manufacturing capabilities.
Frequently Asked Questions
Q1: What is Clarapath Inc.?
Clarapath Inc. is a company that aims to modernize and transform how pathology laboratories process tissue. It has developed a flagship robot called SectionStar that combines robotics, artificial intelligence, and automation to modernize how labs process tissue samples.
Q2: What is SectionStar?
SectionStar is a tissue sectioning and transfer robot designed to increase capacity, reliability, and consistency. It combines robotics, artificial intelligence, and automation to modernize how labs process tissue samples.
Q3: What are the benefits of using SectionStar?
SectionStar can improve slide quality, decrease turnaround time, and reduce cost. It also captures and aggregates never-before-seen data, ultimately benefiting patients with faster results and less subjectivity.
Q4: Who are Clarapath’s investors?
Clarapath’s investors include Northwell Ventures, CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Ventures.
Q5: What is Clarapath’s plan for the future?
Clarapath plans to use the funds to accelerate the commercialization of SectionStar and expand its sales, services, and precision manufacturing capabilities. It also plans to continue research and development to further improve its technology and products.
